Pilot Study of Reduced Venetoclax Exposure
ConditionAcute Myeloid Leukemia in Remission
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthwell Health
About this trial
Pilot Study of Reduced Venetoclax Exposure
Eligibility criteria
Qualifiers
Stated willingness to comply with all study procedures and availability for the duration of the study
Ability to take oral medication and be willing to adhere to the study regimen
5-Azacitidine administered subcutaneously at a dose of 75mg/m2/day X 7 days in combination with VEN (21-28 days/cycle)
Decitabine administered intravenously at a dose of 20mg/m2/day administered in combination with VEN (21-28 days/cycle)
Disqualifiers
Treatment with another investigational drug
Use of growth factor (G-CSF) within the last 14 days prior to C1D1 of trial treatment.
On concomitant targeted therapy such as FLT3 inhibitor or IDH1/2 inhibitor.
Trial design
Treatments tested in this trial
- Azacitidine
- Decitabine
- Venetoclax
Treatment groups
41 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov